Notes
Slide Show
Outline
1
Dupuytrens Disease
  • Chris Bainbridge
2
 
3
History
  • Plater 1614
  • Cline 1808
  • Cooper 1822
  • Dupuytren 1831


4
Basic Science
5
Basic Science
  • Normal Fascia
  • – 95% Type I collagen
  • – 5% Type III collagen
  • Dupuytren’s Fascia
  • – 40% Type III collagen


6
Basic Science
  • Local ischemia leads to fibroblast proliferation
  • Myofibroblasts
  • responsive to growth
  • factors
7
Normal Anatomy
  • • Palmar Aponeurosis
  • • Septi of Legueu and
  • Juvara
  • • Superficial Transverse
  • Palmar Ligament
  • • Pretendinous Band


8
Normal Anatomy
  • • Spiral Band
  • • Natatory Ligament
  • • Lateral Digital Sheath
  • • Cleland’s Ligament
  • • Grayson’s Ligament
  • • Retrovascular Band
  • • Neurovascular Bundle
9
Pathoanatomy
  • • Pathologic change in normal fascia
  • Bands Cords
  • • Myofibroblast produce contractile behavior


10
"MP contracture"
  • MP contracture
    • Pretendinous Cord
  • Thumb web
    • Palmar Aponeurosis
  • Web space
    • Natatory Cord

11
PIP joint
  • Lateral Digital Cord
  • Grayson’s Ligament
  • Central Cord


  • Spiral Cord
  • Retrovascular Cord
12
DIP Joint
  • Lateral Digital Cord
  • Retrovascular Cord


13
Demographics
  • Viking heritage
  • Genetics
    • Complex
    • Multifactorial
    • Mitochondrial element
    • Particular loci now identified
14
Clinical History
  • Age
    • 40 to 60 years (can start younger)
  • Male:Female is 7:1
  • Pathognomonic
    • Nodule
    • Often tender
    • Usually at base of ring finger

15
Clinical examination
  • Flexion Contractures
    • MP, PIP
  • Bilateral
  • Ectopic Deposits


16
Associated Disease
  • Smoking
  • Alcohol
  • Diabetes
  • Epilepsy
17
Trauma
  • NOT related to manual work
  • MAY appear after a single episode of trauma
18
"• Family History"
  • • Family History
  • • Early Onset
  • • Bilateral - Radial
  • • Ectopic Deposits
19
Treatment Indications
  • • “Table Top” Test
  • • MP > 30 degrees
  • • PIP - any contracture
20
Table top tests - Normal
21
Table top tests
22
Assessment
  • Stage 1:  0-45
  • Stage 2:  46-90
  • Stage 3: 91-135
  • Stage 4: 136-180
23
Treatment options
  • • Needle Aponeurotomy
  • • Segmental Fasciectomy
  • • Fasciectomy
  • • Radical Fasciectomy
  • Dermofasciectoy


24
Needle Aponeurotomy
  • Least invasive technique
  • Simple division of the cords
  • Endorsed by NICE
  • Low risk of complications
  • Local anaesthetic out patient procedure
  • No need for physiotherapy
  • Recurrence rate 50% at 5 years
25
Downside to NA
  • Risk of early recurrence
  • Chance of nerve damage, vessel damage (as in all surgery)
  • Possible small skin tears


26
Advantages of NA
  • No risk of skin necrosis
  • No sutures
  • Return to work the next day
  • Much less stiffness
  • No need for a full anaesthetic



27
Segmental fasciectomy
  • Moermans 1990
    • Very simple technique
    • Remove small segments of the cord to release the contracture
    • Low complication rate
    • 23% recurrence at 3 years
    • Local anaesthetic / Axillary block procedure
28
Fasciectomy / Dermofasciectomy
  • Radical surgery
  • Aims to remove all disease
  • High risk of nerve and vessel damage (46% Dias et al)
  • Always needs physio
  • Prolonged recovery (6 weeks +)
  • Recurrence rates 20-40% (3-5 years)
  • 19% feel the problem is as bad after surgery as before
29
Incisions
  • Brunner (zig-zag)
  • Skoog (straight line with Z-plasty)
  • Zig-zag with V-Y extension
30
Wound closure
  • Direct closure with Z-plasty
  • Open palm technique
  • Skin graft
31
 
32
Recurrent Disease
  • 26 to 80% of patients will get recurrence after surgery depending on author
  • Young patients with a high risk
    • Dermofasciectomy with FTG (low risk of recurrence and extension)
  • Further surgery carries a high risk of
    • Nerve damage
    • Cold intolerance
    • Stiffness
  • Needle Aponeurotomy can be repeated for extensions and possibly for recurrent disease


33
New Advances
  • Collagenase injection
    • This is a bacterially derived enzyme which when injected into  a Dupuytrens band will cause rupture without any surgical intervention
    • “AA4500 achieved a 91% success rate for the primary endpoint of less than 5° of contracture in treated joints, including both PIP joints and MP joints, after up to three injections. The placebo group had a 0% response rate (P < 0.001). “